At Replicate, we are focused on staying ahead of the curve – staying ahead of tumor resistance that occurs over time in patients on immuno-oncology regimens – because cancer knows no boundaries. It is estimated that 90% of cancer related deaths come from drug resistance caused by tumor evolution. We have created a solution to a huge problem where no viable solutions or therapies exist.
Replicate is focused on creating novel oncology treatments to prevent and reverse drug resistance through our proprietary self-replicating RNA platform called SynRGY. By deploying our SynRGY technology, we aim to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.